Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation.
Every NR, Cannon CP, Granger C, Moliterno DJ, Aguirre FV, Talley JD, Booth J, Sapp S, Ferguson JJ. Every NR, et al. Among authors: aguirre fv. J Am Coll Cardiol. 1998 Aug;32(2):387-92. doi: 10.1016/s0735-1097(98)00254-x. J Am Coll Cardiol. 1998. PMID: 9708465 Free article.
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Moliterno DJ, et al. Among authors: aguirre fv. Am J Cardiol. 1995 Mar 15;75(8):559-62. doi: 10.1016/s0002-9149(99)80616-x. Am J Cardiol. 1995. PMID: 7887377 Clinical Trial.
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ. Lincoff AM, et al. Among authors: aguirre fv. J Am Coll Cardiol. 1997 Jul;30(1):149-56. doi: 10.1016/s0735-1097(97)00110-1. J Am Coll Cardiol. 1997. PMID: 9207636 Free article. Clinical Trial.
Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.
Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, Topol EJ, Kleiman NS. Khan MM, et al. Among authors: aguirre fv. J Am Coll Cardiol. 1998 Jan;31(1):31-6. doi: 10.1016/s0735-1097(97)00423-3. J Am Coll Cardiol. 1998. PMID: 9426014 Free article. Clinical Trial.
157 results